Wuxi Biologics Stock Earnings Per Share
| WXIBF Stock | USD 1.65 0.00 0.00% |
WuXi Biologics fundamentals help investors to digest information that contributes to WuXi Biologics' financial success or failures. It also enables traders to predict the movement of WuXi Pink Sheet. The fundamental analysis module provides a way to measure WuXi Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to WuXi Biologics pink sheet.
WuXi |
WuXi Biologics Company Earnings Per Share Analysis
WuXi Biologics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current WuXi Biologics Earnings Per Share | 0.14 X |
Most of WuXi Biologics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, WuXi Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, WuXi Biologics has an Earnings Per Share of 0.14 times. This is 98.33% lower than that of the Healthcare sector and 102.92% lower than that of the Biotechnology industry. The earnings per share for all United States stocks is 95.51% higher than that of the company.
WuXi Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WuXi Biologics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of WuXi Biologics could also be used in its relative valuation, which is a method of valuing WuXi Biologics by comparing valuation metrics of similar companies.WuXi Biologics is currently under evaluation in earnings per share category among related companies.
WuXi Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 29.3 B | |||
| Shares Outstanding | 4.22 B | |||
| Shares Owned By Insiders | 14.17 % | |||
| Shares Owned By Institutions | 45.95 % | |||
| Price To Earning | 107.74 X | |||
| Price To Book | 5.92 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 10.29 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.03 B | |||
| Net Income | 3.39 B | |||
| Cash And Equivalents | 9.86 B | |||
| Cash Per Share | 2.36 X | |||
| Total Debt | 640.51 M | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 2.30 X | |||
| Book Value Per Share | 8.25 X | |||
| Cash Flow From Operations | 3.43 B | |||
| Earnings Per Share | 0.14 X | |||
| Price To Earnings To Growth | 0.80 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 34.77 B | |||
| Total Asset | 44.03 B | |||
| Z Score | 32.4 | |||
| Net Asset | 44.03 B |
About WuXi Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WuXi Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WuXi Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WuXi Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in WuXi Biologics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the WuXi Biologics information on this page should be used as a complementary analysis to other WuXi Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for WuXi Pink Sheet analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |